A Thorough QT Study of Teduglutide in Healthy Subjects

Clinical Pharmacology in Drug Development

Volumn 1, Issue 2, 2012, Pages 57-66

  Hartmann, Manfred ^a   Timmer, Wolfgang ^b   Schultz, Armin ^b   Nave, Rüdiger ^a   Luehmann, Reinhold ^a   Krause, Stephan ^a   Lahu, Gezim ^a   Scholpp, Joachim ^a  

^a Nycomed GmbH   (Germany)

^b Department of Statistics   (Germany)

Author keywords

gastrointestinal; peptides; pharmacodynamics; pharmacokinetics; QTc interval

Indexed keywords

MOXIFLOXACIN; PLACEBO; TEDUGLUTIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL DISEASE; HEART CONDUCTION; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84891997970     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1177/2160763X12438745     Document Type: Article

References (22)

1. Yazbeck R.Teduglutide, a glucagon-like peptide 2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.Curr Opin Mol Ther. 2010;12 (6): 798-809.
2. Marier JF,Mouksassi MS,Gosselin NH,Beliveau M,Cyran J,Wallens J.Population pharmacokinetics of teduglutide following repeated subcutanenous administrations in healthy participants and in patients with short bowel syndrome and Crohn's Disease.J Clin Pharmacol. 2010;50:36-49.
3. Jeppesen PB,Gilroy R,Pertkiewicz M,Allard JP,Messing B,O'Keefe SJ.Randomized placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.Gut. 2011;60 (7): 902-914.
4. ICH Topic E 14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers (EMEA/CHMP/ICH/310133/2008). London: ICH; 2008. Accessed at http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/questions-answers-the-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-poten.html.
5. ICH Topic E 14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (CHMP/ICH/2/04). London: ICH; 2005. Accessed at http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf.
6. Salvi V,Karnad DR,Panicker GK,Kothari S.Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.Br J Pharmacol. 2010;159 (1): 34-48.
7. Antzelevitch C.Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.Europace. 2007;9:iv4-iv15.
8. Zhang J.Testing for positive control activity in a thorough QTc study.J Biopharm Stat. 2008;18:517-528.
9. Yan LK,Zhang J,Ng MJ,Dang Q.Statistical characteristics of moxifloxacin-induced QTc effect.J Biopharm Stat. 2010;20 (3): 497-507.
10. Démolis JL,Kubitza D,Tennezé L,Funck-Brentano C.Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.Clin Pharmacol Ther. 2000;68:658-666.
11. Viitasalo M,Karjalainen J.QT intervals at heart rates from 50 to 120 beats per minute during 24-hour electrocardiographic recordings in 100 healthy men. Effects of atenolol.Circulation. 1992;86:1439-1442.
12. Lokhandwala Y,Toal SC.The fallacies of QT correction.Indian Pacing Electrophysiol J. 2003;3 (4): 185-186.
13. Fridericia LS.Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken.Acta Med Scandinav. 1920;53:469-486.
14. Bazett HC.An analysis of time relations of electrocardiograms.Heart. 1920;7:353-367.
15. Recommendations guiding physicians in biochemical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, and amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, 35th World Medical Assembly, Venice, Italy, October 1983, 41st World Medical Assembly, Hong Kong, September 1989, and the 48th General Assembly, Somerset West, Republic of South Africa, October 1996.:.
16. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Official Journal L 281. November23, 1995:31-50. Accessed at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:en:HTML.
17. Stratmann HG,Kennedy HL.Torsades de pointes associated with drugs and toxins: recognition and management.Am Heart J. 1987;113:1470-1482.
18. The European Agency for the evaluation of medicinal products, human medicines evaluation unit. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997: CPMP/986/96. Accessed at http://www.fda.gov/ohrms/dockets/ac/03/briefing/4000B1_12_CPMP%20Points%20to%20consider.pdf.
19. Malik M,Camm AJ.Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.Drug Saf. 2001;24:323-351.
20. Hulhoven R,Rosillon D,Bridson WE,Meeus MA,Salas E,Stockis A.Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study.Clin Ther. 2008;30 (2): 260-270.
21. Timmer W.Cardiac safety-Dr Wolfgang Timmer of CRS examines the conduct of thorough QTc trials in practice from a Phase I CRO's perspective.European Pharmaceutical Contractor. 2008;:.
22. Rodriguez I,Erdman A,Padhi D, et al.Electrocardiographic assessment for therapeutic proteins-scientific discussion.Am Heart J. 2010;160 (4): 627-634.